Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes
Abstract Type 2 diabetes significantly increases cardiovascular risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce major adverse cardiovascular events, heart failure hospitalizations, and death. However, the comparison among GLP-1 RAs on cardiovascular outcomes is limited. We compared...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-06245-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849768827008581632 |
|---|---|
| author | Takefumi Kishimori Takao Kato Atsuyuki Wada Akira Tani Ryosuke Yamaji Jumpei Koike Yoshihiro Iwasaki Takehiro Matsumoto Takafumi Yagi Masaharu Okada |
| author_facet | Takefumi Kishimori Takao Kato Atsuyuki Wada Akira Tani Ryosuke Yamaji Jumpei Koike Yoshihiro Iwasaki Takehiro Matsumoto Takafumi Yagi Masaharu Okada |
| author_sort | Takefumi Kishimori |
| collection | DOAJ |
| description | Abstract Type 2 diabetes significantly increases cardiovascular risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce major adverse cardiovascular events, heart failure hospitalizations, and death. However, the comparison among GLP-1 RAs on cardiovascular outcomes is limited. We compared all-cause death and cardiovascular events in patients using semaglutide or dulaglutide in patients with type 2 diabetes. This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020. We identified 4,691,652 patients with type 2 diabetes, among whom 231,075 initiated semaglutide and 189,103 initiated dulaglutide. After propensity score matching, 171,105 patients were included in each group. The primary outcome measure was all-cause death during the 3-year follow-up period.; secondary outcomes were acute myocardial infarction, stroke, and acute heart failure.Over 3 years, the risk for all-cause death in patients who received semaglutide relative to those who received dulaglutide was significantly lower (4.2% vs. 5.6%, p < 0.001; hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.72–0.78). Similarly, patients who received semaglutide were less likely to have acute myocardial infarction (5.2% vs. 5.6%; HR, 0.94; 95% CI, 0.91–0.97; p < 0.001), stroke (5.8% vs. 6.4%; HR, 0.90; 95% CI, 0.87–0.93; p < 0.001), and acute heart failure (5.3% vs. 6.1%; HR, 0.88; 95% CI, 0.85–0.91; p < 0.001).In this multicenter, retrospective, observational study, semaglutide was associated with lower 3-year risks of all-cause death, acute myocardial infarction, stroke, and acute heart failure compared with dulaglutide in patients with type 2 diabetes. |
| format | Article |
| id | doaj-art-9bcfe815cd4f4d52b9b8352cbfc5d75f |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-9bcfe815cd4f4d52b9b8352cbfc5d75f2025-08-20T03:03:40ZengNature PortfolioScientific Reports2045-23222025-07-011511910.1038/s41598-025-06245-wComparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetesTakefumi Kishimori0Takao Kato1Atsuyuki Wada2Akira Tani3Ryosuke Yamaji4Jumpei Koike5Yoshihiro Iwasaki6Takehiro Matsumoto7Takafumi Yagi8Masaharu Okada9Department of Cardiovascular Medicine, Omi Medical CenterDepartment of Cardiovascular Medicine, Kyoto University Graduate School of MedicineDepartment of Cardiovascular Medicine, Omi Medical CenterDepartment of Cardiovascular Medicine, Omi Medical CenterDepartment of Cardiovascular Medicine, Omi Medical CenterDepartment of Cardiovascular Medicine, Omi Medical CenterDepartment of Cardiovascular Medicine, Omi Medical CenterDepartment of Cardiovascular Medicine, Omi Medical CenterDepartment of Cardiovascular Medicine, Omi Medical CenterDepartment of Cardiovascular Medicine, Omi Medical CenterAbstract Type 2 diabetes significantly increases cardiovascular risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce major adverse cardiovascular events, heart failure hospitalizations, and death. However, the comparison among GLP-1 RAs on cardiovascular outcomes is limited. We compared all-cause death and cardiovascular events in patients using semaglutide or dulaglutide in patients with type 2 diabetes. This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020. We identified 4,691,652 patients with type 2 diabetes, among whom 231,075 initiated semaglutide and 189,103 initiated dulaglutide. After propensity score matching, 171,105 patients were included in each group. The primary outcome measure was all-cause death during the 3-year follow-up period.; secondary outcomes were acute myocardial infarction, stroke, and acute heart failure.Over 3 years, the risk for all-cause death in patients who received semaglutide relative to those who received dulaglutide was significantly lower (4.2% vs. 5.6%, p < 0.001; hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.72–0.78). Similarly, patients who received semaglutide were less likely to have acute myocardial infarction (5.2% vs. 5.6%; HR, 0.94; 95% CI, 0.91–0.97; p < 0.001), stroke (5.8% vs. 6.4%; HR, 0.90; 95% CI, 0.87–0.93; p < 0.001), and acute heart failure (5.3% vs. 6.1%; HR, 0.88; 95% CI, 0.85–0.91; p < 0.001).In this multicenter, retrospective, observational study, semaglutide was associated with lower 3-year risks of all-cause death, acute myocardial infarction, stroke, and acute heart failure compared with dulaglutide in patients with type 2 diabetes.https://doi.org/10.1038/s41598-025-06245-w |
| spellingShingle | Takefumi Kishimori Takao Kato Atsuyuki Wada Akira Tani Ryosuke Yamaji Jumpei Koike Yoshihiro Iwasaki Takehiro Matsumoto Takafumi Yagi Masaharu Okada Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes Scientific Reports |
| title | Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes |
| title_full | Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes |
| title_fullStr | Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes |
| title_full_unstemmed | Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes |
| title_short | Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes |
| title_sort | comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes |
| url | https://doi.org/10.1038/s41598-025-06245-w |
| work_keys_str_mv | AT takefumikishimori comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes AT takaokato comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes AT atsuyukiwada comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes AT akiratani comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes AT ryosukeyamaji comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes AT jumpeikoike comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes AT yoshihiroiwasaki comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes AT takehiromatsumoto comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes AT takafumiyagi comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes AT masaharuokada comparativecardiovascularoutcomesofsemaglutidetodulaglutideinpatientswithtype2diabetes |